RE-SPECT CVT
(2019)Objective
Dabigatran vs. dose-adjusted warfarin in preventing recurrent VTE in patients with cerebral venous thrombosis.
Study Summary
Intervention
Dabigatran 150 mg twice daily vs. dose-adjusted warfarin (INR 2.0–3.0) for 24 weeks. All patients received parenteral anticoagulation (UFH or LMWH) prior to randomization.
Inclusion Criteria
Adults with acute CVT confirmed by imaging, clinically stable after 5–15 days of parenteral anticoagulation. Excluded if associated with CNS infection or major trauma.
Study Design
Arms: Dabigatran vs. Warfarin
Patients per Arm: Dabigatran: 60, Warfarin: 60
Outcome
Bottom Line
In this exploratory randomized trial, patients with CVT treated with either dabigatran or warfarin had a very low risk of recurrent VTE, with zero events observed in either group. The risk of major bleeding was also low and similar between the two medications, suggesting dabigatran may be a safe and effective alternative to warfarin for preventing VTE recurrence after CVT, although the study was not powered for noninferiority.
Major Points
- First and only randomized trial comparing a DOAC to warfarin for cerebral venous thrombosis: 120 patients across 51 centers in 9 countries — an exploratory, hypothesis-generating study.
- Zero recurrent VTEs in EITHER group during 24 weeks — confirming that both dabigatran and warfarin effectively prevent CVT recurrence in the acute/subacute phase.
- Major bleeding was infrequent and similar: 1.7% dabigatran vs 3.3% warfarin — suggesting comparable safety profiles for CVT anticoagulation.
- Cerebral venous recanalization rates were similar (60.0% dabigatran vs 67.3% warfarin) — no evidence that warfarin's mechanism provides superior venous recanalization.
- Higher treatment discontinuation with dabigatran (11.7% vs 0% with warfarin) was unexpected — primarily due to GI side effects, raising adherence concerns specific to CVT patients.
- Not powered for noninferiority — the trial was explicitly exploratory, so equivalence between dabigatran and warfarin cannot be formally concluded.
- Mild CVT population (80% had NIHSS 0; only 30% had hemorrhagic lesions) — results may not apply to severe CVT with large parenchymal hemorrhage or coma.
- First RCT evidence supporting DOAC use in CVT, filling a critical evidence gap — most CVT guidelines previously had no randomized data to inform DOAC recommendations.
- Changed clinical practice: many CVT experts now use DOACs based on RE-SPECT CVT despite its limitations, particularly for patients with mild CVT and no parenchymal hemorrhage.
- Led to EAN/ESO guidelines acknowledging DOACs as a reasonable alternative to warfarin in CVT — with the caveat that evidence is limited to this single exploratory trial.
Study Design
- Study Type
- Exploratory, prospective, randomized (1:1), parallel-group, open-label, multicenter clinical trial with blinded end-point adjudication (PROBE design).
- Randomization
- Yes
- Blinding
- Open-label with blinded endpoint adjudication.
- Sample Size
- 120
- Follow-up
- 24 weeks.
- Centers
- 51
- Countries
- France, Germany, India, Italy, the Netherlands, Poland, Portugal, Russia, Spain
Primary Outcome
Definition: A composite of a new venous thrombotic event (VTE) or a major bleeding event during the 24-week study period.
| Control | Intervention | HR/OR | P-value |
|---|---|---|---|
| 3.3% (2 events) | 1.7% (1 event) | - | No formal hypothesis testing performed. |
Limitations & Criticisms
- Exploratory trial with only 120 patients — severely underpowered to establish noninferiority or detect clinically meaningful differences between dabigatran and warfarin.
- Open-label design may bias management decisions (e.g., threshold for ordering imaging, managing complications) despite blinded endpoint adjudication.
- Predominantly mild CVT population (80% NIHSS 0, only 30% with hemorrhagic lesions) — results cannot be extrapolated to severe CVT with coma, large hemorrhage, or mass effect.
- Zero recurrent VTEs in both groups means the study had no statistical power to compare efficacy — the event rate was far lower than anticipated.
- Higher dabigatran discontinuation (11.7% vs 0%) raises adherence concerns — in real-world practice, this dropout rate could translate to worse outcomes.
- 24-week duration is short — many CVT patients require 3–12+ months of anticoagulation; long-term DOAC safety in CVT is unknown.
- Industry-sponsored by Boehringer Ingelheim (dabigatran manufacturer) — potential conflict of interest in an exploratory trial that could influence prescribing.
- Excluded severe CVT cases (those needing decompressive surgery or with active CNS infection) — the highest-risk patients where anticoagulation decisions are most critical were not studied.
- No guidance on dose adjustment for renal function or drug interactions — dabigatran pharmacokinetics may differ in CVT patients with cerebral edema and altered drug metabolism.
Citation
JAMA Neurol. 2019;76(12):1457-1465.